pioneer 10 semaglutide Efficacy and safety of oral monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial | Diabetologia Composite primary outcome in PIONEER

You may still experience: Constipation affects 24% of semaglutide users in clinical trials

Not appropriate for people with any of the following: Your provider will review your history and labs and discuss alternatives if semaglutide is not a fit

If you've been stable on semaglutide for 3+ months without further weight loss, have reached your target weight, or experience intolerable nausea and constipation, switching to a dual-mechanism compound like tirzepatide may offer better results

TB500: Usually given as a shot under the skin or into the muscle

These mechanisms make it a promising therapy for durable glycaemic control in people with type 2 diabetes, especially those who are overweight or obese

GLP-1 Analogs can have a number of benefits, including: Significant weight reduction when combined with diet and exercise Improved blood sugar control Reduced risk of major cardiovascular events Health benefits like improved blood pressure and cholesterol levels In the Semaglutide Treatment Effect in People with Obesity (STEP) study, published in The New England Journal of Medicine , participants receiving the once-weekly semaglutide lost an average of 34 pounds over 68 weeks, showcasing its effectiveness in managing obesity